Meta-Analysis of the Effect of the Oncotype DX® Assay Recurrence Score® (RS) on Clinical Decision-Making


Meta-Analysis of the Effect of the Oncotype DX® Assay Recurrence Score® (RS) on Clinical Decision-Making
Slides from a presentation at SABCS 2010 and transcribed comments from a recent interview with Harold J Burstein, MD, PhD (12/22/10)

Hornberger J, Chien R. Meta-analysis of the decision impact of the 21-gene breast cancer Recurrence Score in clinical practice. San Antonio Breast Cancer Symposium 2010;Abstract P2-09-06.

Dr Burstein is Associate Professor of Medicine at Harvard Medical School in Boston, Massachusetts.